Regeneron Pharmaceuticals (REGN) Revenue and Net Income History

Historical revenue, operating income and net income for Regeneron Pharmaceuticals (REGN) over the last 10 years. The current TTM revenue for Regeneron Pharmaceuticals as of October 23, 2017 is $4.86B.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $46.394B $4.860B
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)